A rare case describes onset of myasthenia gravis, neuromyelitis optica, and anti-N-methyl-D-aspartate receptor in one woman, ...
LOS ANGELES, May 21, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, ...
Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) is a prescription medicine that is used to treat certain muscle and nerve conditions. It is a combination of two medicines, efgartigimod alfa and ...
Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune disease that can cause severe numbness, weakness and disability. In a recent interview hosted by Sanofi, Dr. Jeffrey ...
Dr. Lin joins Nuvig to advance NVG-2089 through Phase 2 studies in chronic inflammatory demyelinating polyneuropathy and ...
Neuromyelitis optica spectrum disorder (NMOSD) and related demyelinating diseases, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), represent a spectrum of autoimmune ...
Argenx SE gained U.S. FDA approval of subcutaneously given Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing autoimmune disease therapies targeting the neonatal Fc receptor [FcRn]. IMVT's leading drug candidate, Batoclimab, shows ...
September 23, 2009 (Düsseldorf, Germany) — Investigators have identified cases of autoimmune disorders after immunization with the quadrivalent vaccine Gardasil. The Merck product is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback